Clinical
临床
基本信息
- 批准号:7685017
- 负责人:
- 金额:$ 38.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-15 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAdherenceAdvertisementsAnti-Retroviral AgentsAppointmentAreaArtsBasic ScienceBehavioralBehavioral SciencesBiometryCharacteristicsClinicClinicalClinical ResearchCollaborationsCollectionComplexComputer softwareComputersDNA SequenceDataData AnalysesDatabasesDevelopmentDisciplineElectronicsEnsureEquipmentFacultyFosteringFundingHIVHealth PersonnelHealth Services AccessibilityHealth behaviorHealthcareHuman ResourcesImmune responseIndividualInformaticsInstitutionInternationalInvestigationLeadLeadershipLinkMailsMedical RecordsMental disordersMentorsMethodsNewsletterObservational StudyOperative Surgical ProceduresOutcomePathogenesisPatientsPharmaceutical PreparationsPlasmapheresisPlayPoliciesPositioning AttributeProcessProductivityProtocols documentationPublicationsPublishingResearchResearch DesignResearch MethodologyResearch PersonnelResearch SubjectsResearch TrainingResourcesRoleSamplingSeasonsServicesShippingShipsSiteSpecimenStreamStudentsSubstance abuse problemSystemTechniquesTechnologyTrainingTranslational ResearchUpdateWorkZambiabasecareercohortcomputerizedcost effectivenessdesignimprovedinnovationinterestmeetingsmemberprospectivequality assurancerepositoryresearch studyresponseskillsstatisticssuccesssystems researchvaccine developmentvirologyweb site
项目摘要
The Clinical Core has been in operation for twenty years to provide services that foster the translational interface
between basic science, clinical, behavioral, and epidemiologic investigators and HIV-infected patients. The Specific
Aims of the Clinical Core are:
1. To provide a Comprehensive Specimen Repository offering the efficient collection, processing, storage,
quality assurance tracking, distribution, and shipping of clinical specimens obtained from wellcharacterized
patients for collaborative investigations involving multiple research disciplines.
2. To provide an innovative Computerized Database and Informatics Service¿the resources and
equipment to store and access complex, interactive data and the expertise to assist with study design,
identify subjects who meet entry criteria for research protocols, conduct appropriate data analyses and
provide detailed and relevant interpretation of results.
3. To establish new methods and technologies to make clinical samples more readily accessible to CFAR
members realizing that despite the numerous successes we have had in fostering innovative translational
research, we must strive to improve this process.
4. To provide Research Training Services to support all levels (from students to research staff to seasoned
faculty updating their skills) of domestic and international clinical research.
While each of these services has been in operation since the beginning of our CFAR, each continues to grow and
diversify substantially in response to investigator needs. Publications requiring Clinical Core services have continued
to increase every year during the last funding period. Specimens are integrally linked with information in the
Computerized Database, and this synergy has played an important role in new discoveries related to HIV
pathogenesis, understanding immune responses and vaccine development. Recently, the medical record system and
research database have become fully electronic, utilizing software completely designed and managed by CFAR
investigators with expertise in informatics, statistics and computer technology. These advancements place CFAR
investigators in a unique position to lead collaborative clinical database and outcomes-based national and international
projects, and to contribute meaningfully to policy debates regarding health care access and cost-effectiveness. A
variety of domestic research training services have been strengthened, while international research training efforts are
best exemplified by Clinical Core support, in full collaboration with the International Core. These Clinical Core services
are essential for the conduct of a vast array of HIV/AIDS research at DAB and around the world.
临床核心已经运作了二十年,提供促进翻译界面的服务
基础科学、临床、行为和流行病学调查人员与HIV感染者之间的关系。具体
临床核心的目的是:
1.提供一个全面的标本库,提供有效的收集,处理,储存,
质量保证跟踪、分发和运输从表征良好的
患者进行涉及多个研究学科的合作研究。
2.提供创新的计算机化数据库和信息服务,
用于存储和访问复杂的交互式数据的设备以及用于协助研究设计的专业知识,
确定符合研究方案入选标准的受试者,进行适当的数据分析,
提供详细和相关的结果解释。
3.建立新的方法和技术,使临床样本更容易获得CFAR
成员们认识到,尽管我们在促进创新翻译方面取得了许多成功,
研究,我们必须努力改善这一进程。
4.提供研究培训服务,以支持各级(从学生到研究人员,以经验丰富的
教师更新他们的技能)的国内和国际临床研究。
虽然这些服务中的每一个都是从我们的CFAR开始运行的,但每一个都在继续增长,
根据调查人员的需求进行大幅多样化。需要临床核心服务的出版物继续
在上一个供资期间,每年都在增加。样本与中的信息紧密相连
计算机化数据库,这种协同作用在与艾滋病毒相关的新发现中发挥了重要作用
发病机制,了解免疫反应和疫苗开发。最近,医疗记录系统和
研究数据库已完全电子化,使用完全由CFAR设计和管理的软件
具有信息学、统计学和计算机技术专门知识的调查员。这些进步将CFAR
研究者处于独特的地位,能够领导基于国家和国际的协作临床数据库和结局
项目,并有意义地促进有关卫生保健的获取和成本效益的政策辩论。一
各种国内研究培训服务得到加强,而国际研究培训工作也得到加强。
最好的例证是临床核心支持,与国际核心充分合作。这些临床核心服务
对于在DAB和世界各地进行大量的HIV/AIDS研究至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul A. Goepfert其他文献
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
mRNA 第二剂 COVID-19 疫苗加强接种在 COVAIL 试验受试者中的中和抗体免疫相关性
- DOI:
10.1038/s41467-025-55931-w - 发表时间:
2025-01-17 - 期刊:
- 影响因子:15.700
- 作者:
Bo Zhang;Youyi Fong;Lauren Dang;Jonathan Fintzi;Shiyu Chen;Jing Wang;Nadine G. Rouphael;Angela R. Branche;David J. Diemert;Ann R. Falsey;Daniel S. Graciaa;Lindsey R. Baden;Sharon E. Frey;Jennifer A. Whitaker;Susan J. Little;Satoshi Kamidani;Emmanuel B. Walter;Richard M. Novak;Richard Rupp;Lisa A. Jackson;Chenchen Yu;Craig A. Magaret;Cindy Molitor;Bhavesh Borate;Sydney Busch;David Benkeser;Antonia Netzl;Derek J. Smith;Tara M. Babu;Angelica C. Kottkamp;Anne F. Luetkemeyer;Lilly C. Immergluck;Rachel M. Presti;Martín Bäcker;Patricia L. Winokur;Siham M. Mahgoub;Paul A. Goepfert;Dahlene N. Fusco;Robert L. Atmar;Christine M. Posavad;Jinjian Mu;Mat Makowski;Mamodikoe K. Makhene;Seema U. Nayak;Paul C. Roberts;Peter B. Gilbert;Dean Follmann - 通讯作者:
Dean Follmann
Identification of soluble biomarkers that associate with distinct manifestations of long COVID
与长期 COVID 不同表现形式相关的可溶性生物标志物的鉴定
- DOI:
10.1038/s41590-025-02135-5 - 发表时间:
2025-04-30 - 期刊:
- 影响因子:27.600
- 作者:
Yu Gao;Curtis Cai;Sarah Adamo;Elsa Biteus;Habiba Kamal;Lena Dager;Kelly L. Miners;Sian Llewellyn-Lacey;Kristin Ladell;Pragati S. Amratia;Kirsten Bentley;Simon Kollnberger;Jinghua Wu;Mily Akhirunnesa;Samantha A. Jones;Per Julin;Christer Lidman;Richard J. Stanton;Paul A. Goepfert;Michael J. Peluso;Steven G. Deeks;Helen E. Davies;Soo Aleman;Marcus Buggert;David A. Price - 通讯作者:
David A. Price
Circulating SARS-CoV-2sup+/sup megakaryocytes are associated with severe viral infection in COVID-19
循环的 S 型冠状病毒 2 型阳性巨核细胞与 COVID-19 中的严重病毒感染有关
- DOI:
10.1182/bloodadvances.2022009022 - 发表时间:
2023-08-08 - 期刊:
- 影响因子:7.100
- 作者:
Seth D. Fortmann;Michael J. Patton;Blake F. Frey;Jennifer L. Tipper;Sivani B. Reddy;Cristiano P. Vieira;Vidya Sagar Hanumanthu;Sarah Sterrett;Jason L. Floyd;Ram Prasad;Jeremy D. Zucker;Andrew B. Crouse;Forest Huls;Rati Chkheidze;Peng Li;Nathaniel B. Erdmann;Kevin S. Harrod;Amit Gaggar;Paul A. Goepfert;Maria B. Grant;Matthew Might - 通讯作者:
Matthew Might
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
在 ENSEMBLE 单剂量 Ad26.COV2.S 疫苗效力试验中与预防严重/危重 COVID-19 相关的中和抗体
- DOI:
10.1038/s41467-024-53727-y - 发表时间:
2024-11-12 - 期刊:
- 影响因子:15.700
- 作者:
Lindsay N. Carpp;Ollivier Hyrien;Youyi Fong;David Benkeser;Sanne Roels;Daniel J. Stieh;Ilse Van Dromme;Griet A. Van Roey;Avi Kenny;Ying Huang;Marco Carone;Adrian B. McDermott;Christopher R. Houchens;Karen Martins;Lakshmi Jayashankar;Flora Castellino;Obrimpong Amoa-Awua;Manjula Basappa;Britta Flach;Bob C. Lin;Christopher Moore;Mursal Naisan;Muhammed Naqvi;Sandeep Narpala;Sarah O’Connell;Allen Mueller;Leo Serebryannyy;Mike Castro;Jennifer Wang;Christos J. Petropoulos;Alex Luedtke;Yiwen Lu;Chenchen Yu;Michal Juraska;Nima S. Hejazi;Daniel N. Wolfe;Jerald Sadoff;Glenda E. Gray;Beatriz Grinsztejn;Paul A. Goepfert;Linda-Gail Bekker;Aditya H. Gaur;Valdilea G. Veloso;April K. Randhawa;Michele P. Andrasik;Jenny Hendriks;Carla Truyers;An Vandebosch;Frank Struyf;Hanneke Schuitemaker;Macaya Douoguih;James G. Kublin;Lawrence Corey;Kathleen M. Neuzil;Dean Follmann;Richard A. Koup;Ruben O. Donis;Peter B. Gilbert - 通讯作者:
Peter B. Gilbert
Skewed fate and hematopoiesis of CD34sup+/sup HSPCs in umbilical cord blood amid the COVID-19 pandemic
在 COVID-19 大流行期间,脐带血中 CD34+造血祖细胞的命运和造血发生了扭曲。
- DOI:
10.1016/j.isci.2022.105544 - 发表时间:
2022-12-22 - 期刊:
- 影响因子:4.100
- 作者:
Benjamin K. Estep;Charles J. Kuhlmann;Satoru Osuka;Gajendra W. Suryavanshi;Yoshiko Nagaoka-Kamata;Ciearria N. Samuel;Madison T. Blucas;Chloe E. Jepson;Paul A. Goepfert;Masakazu Kamata - 通讯作者:
Masakazu Kamata
Paul A. Goepfert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul A. Goepfert', 18)}}的其他基金
The impact of HIV adaptation to CD8 T cells on infection and viral control
HIV 对 CD8 T 细胞的适应对感染和病毒控制的影响
- 批准号:
10245517 - 财政年份:2020
- 资助金额:
$ 38.66万 - 项目类别:
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
定义 HIV-1 适应与 CD4 T 细胞反应的生物学相关性
- 批准号:
9418347 - 财政年份:2017
- 资助金额:
$ 38.66万 - 项目类别:
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
定义 HIV-1 适应与 CD4 T 细胞反应的生物学相关性
- 批准号:
10186453 - 财政年份:2017
- 资助金额:
$ 38.66万 - 项目类别:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
HIV 疫苗 T 细胞表位选择的合理方法
- 批准号:
8797988 - 财政年份:2014
- 资助金额:
$ 38.66万 - 项目类别:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
HIV 疫苗 T 细胞表位选择的合理方法
- 批准号:
9087090 - 财政年份:2014
- 资助金额:
$ 38.66万 - 项目类别:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
HIV 疫苗 T 细胞表位选择的合理方法
- 批准号:
8892071 - 财政年份:2014
- 资助金额:
$ 38.66万 - 项目类别:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
HIV 疫苗 T 细胞表位选择的合理方法
- 批准号:
9302653 - 财政年份:2014
- 资助金额:
$ 38.66万 - 项目类别:
Analysis of Variant Epitope Specific CD8 T-Cells to Optimize HIV Vaccine Design
分析变异表位特异性 CD8 T 细胞以优化 HIV 疫苗设计
- 批准号:
8546018 - 财政年份:2012
- 资助金额:
$ 38.66万 - 项目类别:
CTL and HIV Polymorphisms in Heterosexual Transmission
异性传播中的 CTL 和 HIV 多态性
- 批准号:
8069728 - 财政年份:2010
- 资助金额:
$ 38.66万 - 项目类别:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
HIV-1 隐性表位:对疫苗设计的影响
- 批准号:
8131729 - 财政年份:2009
- 资助金额:
$ 38.66万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 38.66万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 38.66万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 38.66万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 38.66万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 38.66万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 38.66万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 38.66万 - 项目类别: